<?xml version="1.0" encoding="UTF-8"?>
<p>Through EPITT, MSs and the EMA exchange safety information on (1) concerns with potential major impact on the known risk‐benefit balance of a medicine, possibly warranting prompt regulatory action and communication (in the form of Rapid Alerts) or (2) other less urgent concerns (in the form of Non‐Urgent Information).</p>
